Journal of Clinical Oncology, Vol 16, 3230-3237, Copyright © 1998 by American Society of Clinical Oncology
Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain
R Kaplan, WC Parris, ML Citron, D Zhukovsky, RF Reder, BJ Buckley and RF Kaiko
Department of Anesthesiology Pain Service, Montefiore Medical Center, Bronx, NY, USA.
PURPOSE: This study compared the clinical efficacy of oxycodone
hydrochloride controlled-release (CR) tablets administered every 12 hours
with immediate-release (IR) oxycodone tablets administered four times daily
in patients with cancer-related pain. PATIENTS AND METHODS: Cancer patients
who required therapy for moderate to severe pain were randomized to CR
oxycodone every 12 hours (n=81) or IR oxycodone four times daily (n=83) for
5 days in a multicenter, double-blind study. Pain intensity was assessed
four times daily (categorical scale of none, slight, moderate, and severe);
acceptability of therapy was assessed twice daily (categorical scale of
very poor, poor, fair, good, and excellent). RESULTS: Pain intensity
remained slight during the study, with mean oxycodone doses of 114 mg/d
(range, 20 to 400 mg/d) for CR and 127 mg/d (range, 40 to 640 mg/d) for IR.
Acceptability of therapy was fair to good with both treatments. While
standard conversion ratios provided an acceptable dose for many patients, a
protocol amendment that allowed initial titration and use of rescue
medication reduced the discontinuation rate for lack of acceptable pain
control (from 34% to 4% with CR and from 31% to 19% with IR before and
after amendment, respectively) without increasing the discontinuation rate
for adverse events (from 8% to 7% with CR and from 13% to 11% with IR).
Fewer adverse events were reported with CR (109) than with IR (186)
oxycodone (P=.006). CONCLUSION: CR oxycodone every 12 hours was as
effective as IR oxycodone four times daily in managing moderate to severe
cancer-related pain and was associated with fewer reports of adverse
events.
This article has been cited by other articles:
|
|
|
|
 
A. Kogan, B. Medalion, E. Raanani, E. Sharoni, A. Stamler, N. Pak, B. A. Vidne, and L. A. Eidelman
Early oral analgesia after fast-track cardiac anesthesia: [L'analgesie orale precoce apres la technique acceleree d'anesthesie cardiaque]
Can J Anesth,
April 1, 2007;
54(4):
254 - 261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Koizumi, H. Toma, K.-i. Watanabe, K. Katayama, M. Kawahara, K. Matsui, H. Takiuchi, K. Yoshino, N. Araki, K. Kodama, et al.
Efficacy and Tolerability of Cancer Pain Management with Controlled-release Oxycodone Tablets in Opioid-naive Cancer Pain Patients, Starting with 5 mg Tablets
Jpn. J. Clin. Oncol.,
October 1, 2004;
34(10):
608 - 614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Robards
Transdermal fentanyl in the hospice: A survey of rescue dosing and pain control
American Journal of Hospice and Palliative Medicine,
January 1, 2001;
18(1):
47 - 50.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. H. Roth, R. M. Fleischmann, F. X. Burch, F. Dietz, B. Bockow, R. J. Rapoport, J. Rutstein, and P. G. Lacouture
Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain: Placebo-Controlled Trial and Long-term Evaluation
Arch Intern Med,
March 27, 2000;
160(6):
853 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Abrahm and for the ACP-ASIM End-of-Life Care Consensus Panel
Management of Pain and Spinal Cord Compression in Patients with Advanced Cancer
Ann Intern Med,
July 6, 1999;
131(1):
37 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Opioid Treatment of Cancer Pain
Journal Watch (General),
October 23, 1998;
1998(1023):
2 - 2.
[Full Text]
|
|
|
|
